Overview

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-10

Target enrollment:

Participant gender:

Summary

This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Qilu Hospital of Shandong University

Treatments:

Chemotherapy, Adjuvant
Neoadjuvant Therapy
Surgical Procedures, Operative